Chugai relays Roche interim Phase III data on sefaxersen for IgA nephropathy
Key highlights
- Chugai linked to a Roche media release issued October 23, 2026.
- Roche presented detailed interim analysis from the global Phase III IMAgINATION study at ASN Kidney Week 2026.
- The IMAgINATION study evaluated sefaxersen in people with IgA nephropathy (IgAN).
- Roche reported that sefaxersen significantly reduced proteinuria in the interim analysis.
Chugai notice
Chugai Pharmaceutical announced that Roche issued a media release on October 23, 2026, regarding a presentation at ASN Kidney Week 2026.
Study details
The presentation covered detailed interim analysis data from the global Phase III IMAgINATION study, which evaluated sefaxersen in people with IgA nephropathy (IgAN).
Key outcome
Roche reported the interim analysis showed a significant reduction in proteinuria.
Reference
Chugai provided a link to Roche’s media release: https://www.roche.com/media/releases/med-cor-2026-10-23
Source: Chugai Pharmaceutical